ES2566337T3 - Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes - Google Patents

Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes Download PDF

Info

Publication number
ES2566337T3
ES2566337T3 ES06735487.8T ES06735487T ES2566337T3 ES 2566337 T3 ES2566337 T3 ES 2566337T3 ES 06735487 T ES06735487 T ES 06735487T ES 2566337 T3 ES2566337 T3 ES 2566337T3
Authority
ES
Spain
Prior art keywords
mhz
yield
phenyl
phenoxy
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06735487.8T
Other languages
English (en)
Spanish (es)
Inventor
Bishwajit Nag
Abhijeet Nag
Debendranath Dey
Shiv Kumar Agarwal
Partha Neogi
Gaddam Om Reddy
Sangamesh Badiger
Gajendra Singh
Surendra Kumar Pandey
Santhanagopalan Chithra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bexel Pharmaceuticals Inc
Original Assignee
Bexel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bexel Pharmaceuticals Inc filed Critical Bexel Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2566337T3 publication Critical patent/ES2566337T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES06735487.8T 2005-02-17 2006-02-17 Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes Expired - Lifetime ES2566337T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
INDE03472005 2005-02-17
IN347DE2005 2005-02-17
US96718 2005-03-31
US11/096,718 US7521465B2 (en) 2003-01-17 2005-03-31 Diphenyl ether derivatives
PCT/US2006/005846 WO2006089225A1 (en) 2005-02-17 2006-02-17 5- [4- (4- (2 -amino- 2 -methoxycarbonylethyl) phenoxy) benzilidene] thiazolidin-2 , 4-dion e derivatives and related compounds for reducing glucose, cholesterol and triglyceride levels in plasma

Publications (1)

Publication Number Publication Date
ES2566337T3 true ES2566337T3 (es) 2016-04-12

Family

ID=36570583

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06735487.8T Expired - Lifetime ES2566337T3 (es) 2005-02-17 2006-02-17 Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes

Country Status (9)

Country Link
US (1) US7521465B2 (https=)
EP (1) EP1848700B1 (https=)
JP (1) JP5134974B2 (https=)
KR (1) KR20070105364A (https=)
CA (1) CA2598087C (https=)
ES (1) ES2566337T3 (https=)
HU (1) HUE028882T2 (https=)
PL (1) PL1848700T3 (https=)
WO (1) WO2006089225A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US9969977B2 (en) * 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US7521465B2 (en) 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
EP2066800A2 (en) * 2006-08-04 2009-06-10 Decode Genetics EHF Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
US20090069313A1 (en) * 2007-09-06 2009-03-12 Orchid Research Laboratories Ltd. Novel MAO-A inhibitors
WO2009143041A1 (en) 2008-05-20 2009-11-26 Merck & Co., Inc. Efficient production of heterologous proteins using mannosyl transferase inhibitors
CN103108634B (zh) * 2010-07-28 2015-08-12 幽兰化学医药有限公司 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物
US9056862B2 (en) 2011-05-10 2015-06-16 National University Corporation Kobe University Thioxothiazolidine derivative having Ras function inhibitory effect
US11117877B2 (en) 2014-11-21 2021-09-14 Bsim Therapeutics, S.A. 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
TW202019923A (zh) * 2018-07-16 2020-06-01 義大利商吉斯藥品公司 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0228168A (ja) * 1988-04-14 1990-01-30 Sankyo Co Ltd チアゾール誘導体
US20020049240A1 (en) 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
TW268952B (https=) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5527546A (en) 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
ATE271128T1 (de) 1995-05-11 2004-07-15 Applied Research Systems Inhibitoren der il-6 aktivitaet
TW577875B (en) 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6699896B1 (en) 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
WO1999064417A2 (en) 1998-06-05 1999-12-16 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
WO2000000194A1 (en) 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US6664281B1 (en) 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU757729B2 (en) 1999-04-07 2003-03-06 Sankyo Company Limited Amine derivatives
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
TWI284533B (en) 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
KR20010099634A (ko) 1999-07-01 2001-11-09 할리 켈빈 비. 텔로머라제 저해제 및 그 사용 방법
CN1155586C (zh) 1999-08-23 2004-06-30 杏林制药株式会社 取代的苄基噻唑烷-2,4-二酮衍生物
JP2003508391A (ja) 1999-08-31 2003-03-04 マキシア・ファーマシューティカルズ・インコーポレイテッド ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用
JP2001199888A (ja) 2000-01-24 2001-07-24 Fujimoto Brothers:Kk 糖尿病治療剤
JP2001308814A (ja) 2000-04-19 2001-11-02 Hitachi Ltd フレーム構成自動識別通信装置
EP1148054B1 (en) 2000-04-21 2005-11-23 Pfizer Products Inc. Thyroid receptor ligands
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
CA2460541A1 (en) 2001-09-14 2003-04-03 Helle Birk Olsen Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
JP2005513026A (ja) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
US7521465B2 (en) 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US6794401B2 (en) 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
JP2007523842A (ja) 2003-03-11 2007-08-23 ノボ　ノルディスク　アクティーゼルスカブ 酸安定化されたインスリンを含有する薬学的製剤
US7087576B2 (en) 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers

Also Published As

Publication number Publication date
JP5134974B2 (ja) 2013-01-30
KR20070105364A (ko) 2007-10-30
CA2598087C (en) 2014-05-27
HUE028882T2 (en) 2017-01-30
JP2008530242A (ja) 2008-08-07
US20050288341A1 (en) 2005-12-29
US7521465B2 (en) 2009-04-21
WO2006089225A1 (en) 2006-08-24
EP1848700A1 (en) 2007-10-31
EP1848700B1 (en) 2015-12-30
CA2598087A1 (en) 2006-08-24
PL1848700T3 (pl) 2016-08-31

Similar Documents

Publication Publication Date Title
ES2566337T3 (es) Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes
ES2546808T3 (es) Reactivo para síntesis orgánica y método de reacción de síntesis orgánica con dicho reactivo
US8501960B2 (en) Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
CN102838523A (zh) 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
ES2659337T3 (es) Derivados de quinazolina y su uso como inhibidores de ADN metiltransferasa
ES2633838T3 (es) Método para preparar derivados tricíclicos
ES2597652T3 (es) Síntesis optimizada de ácidos biliares puros, cristalinos, no polimórficos, con tamaño de partícula definido
Looper et al. Syntheses of the cylindrospermopsin alkaloids
CN103387601B (zh) 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
ES2991081T3 (es) Procedimiento para preparar 2-(3,5-diclorofenil)-6-benzoxazolcarboxilato de 1-desoxi-1-metilamino-D-glucitol
US9771317B2 (en) Process for preparing lacosamide and related compounds
JP4393376B2 (ja) フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用
US10676443B2 (en) Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile
EA024688B1 (ru) Способ получения ситаглиптина и его фармацевтически приемлемых солей
CN113234037A (zh) Z-2-(2-酰基亚甲基)噻唑烷-4-酮类衍生物及其制备方法和应用
TWI290554B (en) Process for preparation 5-(1-piperazinyl)-benzofuran-2-carboxamide by transition metal-catalyzed amination
CN100480234C (zh) N-(n-苯甲酰基-苯丙氨酰基)-苯丙氨酸二肽衍生物及其制备方法和用途
US20240300930A1 (en) Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
WO2011065420A1 (ja) ６－置換－１－メチル－１ｈ－ベンズイミダゾール誘導体の製造法及びその製造中間体
ES2912409T3 (es) Intermedios y procesos para la preparación de linagliptina y sus sales
JP2006500409A5 (https=)
CN101445468A (zh) 对氨基苯甲酸拟二肽酯及其制备方法和应用
EP1511728B1 (fr) Derives d oxophenyl-cyclohexyl-propanolamine, leur preparati on et leur application en therapeutique
CN103421083A (zh) 具有1,2,3-三氮唑结构的抗登革热病毒杂环肽类化合物及其制备方法和用途
WO2014125233A2 (fr) Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle